Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-03 · accession 0001209191-22-001651 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-05 | 2022-01-03 | NTLA | Hicks Derek | EVP, Chief Business Off | A - Grant | $0.00 | +19.1K | 19.1K | New | $0 |
| D | 2022-01-05 | 2022-01-03 | NTLA | Hicks Derek | EVP, Chief Business Off | A - Grant | $0.00 | +25.0K | 25.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | A | A | 19,118 | $0.00 | 19,118 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Derivative | Stock option (right to buy) | 2022-01-03 | A | A | 25,000 | $0.00 | 25,000 | D | $118.99 · — to 2032-01-02 | 25,000 Common Stock | (F2) This option was granted on January 3, 2022 with respect to 25,000 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 25% vesting on December 20, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. |